海藻酸盐控释微球的制备及其体外释药特性  

Fabrication of Alginate Microsphere for Controlled Release and Investigation of Its Release Characteristics in Vitro

作　　者：何清义[1] 温立升[1] 李强[1] 许建中[1] 罗飞[1] 

机构地区：[1]第三军医大学附属西南医院骨科,重庆400038

出　　处：《生物医学工程学杂志》2007年第6期1301-1304,共4页Journal of Biomedical Engineering

基　　金：国家自然基金青年基金资助项目(30300357)

摘　　要：研制白蛋白海藻酸钠(BSA-海藻酸钙微球)控释微球,并对其体外释药特性等进行考察,为应力控释VEGF促进组织工程骨血管化提供理论依据。以海藻酸钠为载体,采用W/O乳化-离子交联法制备BSA-海藻酸钙微球;检测粒径大小、外观、包封率等理化特性;考察微球的体外释药特性。微球球形圆整,分散性好,平均粒径为230±60μm,载药量达80.3μg/mg,包封率为61%;微球的体外释药速率平稳,周期达2周余。海藻酸钠可以作为蛋白、多肽类药物的可生物降解辅料;乳化离子交联法的制备工艺简便,有利于蛋白、多肽类药物结构和功能的稳定性并有效延长其作用时间。This study sought to producte alginate sodium microsphere for controlled release bovine serum albumin（BSA） and to investigate the protein release profile of the BSA- alginate sodium microsphere in vitro, which threw some light on the angiogenesis of tissue engineering bone with vascular endothelial growth factor （VEGF） controlled release under stress. The BSA- alginate sodium microsphere was fabricated with W/O emulsification and ion cross-linking method using alginate sodium. The appearance, microsphere diameter and envelopment rate were detected, and the release characteristics of the BSA- alginate sodium microsphere in vitro was investigated. The alginate microsphere was found to be spherical in shape and evenly distributed. Its mean grain diameter was determined to be 230±60μm, carrying capacity 80. 3 μg/mg and envelopment rate 61%. Smooth controlled release in BSA- alginate sodium microsphere was shown to last more than 2 weeks. Alginate sodium proved an excellent biodegradable material for protein or polypeptide controlled release. The emulsification and ion cross-linking method was noted to be simple; it was propitious to the structural and functional stablility of protein or polypeptide,thus leading to the prolonged efficacious time of the microsphere.

关 键 词：海藻酸钠 微球 控释 

分 类 号：R318.08[医药卫生—生物医学工程]